Advertisement
Organisation › Details
N-of-One Inc.
N-of-One is a Concord, Massachusetts, based privately held firm that began in 2008 as a cancer patient advocacy company and evolved into a molecular decision support company. N-of-One employs 41 people and eight practicing / treating oncologists as contractors. N-of-One has built a proprietary somatic cancer database with more than 125,000 patient samples, and they keep the rights to the anonymized data interpreted to grow their database. N-of-One is the leader in identifying patient-specific therapeutic options for precision medicine in oncology by leveraging its proprietary knowledge base and its team of oncologists and Ph.D. scientists to integrate molecular data from multiple tests. N-of-One’s solutions have provided therapeutic options, including clinical trials, for tens of thousands of patient cases across hundreds of cancer types. N-of-One partners with leading hospital systems, cancer centers, and commercial labs around the world. *
Start | 2008-01-01 established | |
Group | Qiagen (Group) | |
Industry | molecular diagnostics | |
Industry 2 | oncology | |
Person | Cournoyer, Chris (N-of-One 201611 CEO) | |
Street | 561 Virginia Road Suite 300 | |
City | 01742 Concord, MA | |
Tel | +1-617-202-9808 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | B: 11 to 50 (2019-01-07) |
* Document for »About Section«: | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Qiagen (Group)
- [1] Qiagen N.V.. (1/4/24). "Press Release: Qiagen to Accelerate Investments into Qiagen Digital Insights Bioinformatics Business". Venlo....
- [2] Qiagen N.V.. (1/3/24). "Press Release: Qiagen Expands Business in Middle East with New Regional Headquarters and Major Projects". Venlo, Muscat & Ryadh....
- [3] Qiagen N.V.. (9/25/23). "Press Release: Qiagen Enhances QIAwave Portfolio with New Eco-friendlier Nucleic Acid Extraction Kits". Venlo....
- [4] Qiagen N.V.. (9/11/23). "Press Release: Qiagen Launches API to Streamline Access to World-leading Biomedical Data for AI Integration". Venlo & Redwood City, CA....
- [5] Qiagen N.V.. (8/8/23). "Press Release: Qiagen Delivers Ahead of Outlook for Q2 2023 with 9% CER Sales Growth in Non-COVID Products and Updates 2023 Full-year Outlook". Venlo....
- [6] Qiagen N.V.. (8/7/23). "Press Release: Qiagen Receives FDA Approval for Companion Diagnostic to Blueprint Medicines’ Ayvakit (avapritinib) in Gastrointestinal Stromal Tumors". Venlo & Germantown, MD....
- [7] Qiagen N.V.. (7/26/23). "Press Release: Bio-Rad and Qiagen Announce Patent Settlement and Cross-licensing Agreement". Venlo....
- [8] Qiagen N.V.. (6/15/23). "Press Release: Qiagen’s QuantiFERON-TB Gold Plus Shows Unique Clinical Value with CD8 Technology in New Meta-analysis of Tuberculosis Screening". Venlo....
- [9] Qiagen N.V.. (6/13/23). "Press Release: Danish National Genome Center Selects Qiagen for Variant Interpretation in Oncology Genome Sequencing". Venlo & Redwood City, CA....
- [10] Qiagen N.V.. (5/15/23). "Press Release: Qiagen Expands Enzyme Offering to Support Individual Life Science Research Labs Worldwide". Berlin....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top